87587-62-0

Basic information

• Product Name: Benzene, 4-azido-1,2-dimethoxy-
• CAS NO: 87587-62-0
• Molecular Formula: C8H9N3O2
• Molecular Weight: 179.178
• Mol File: 87587-62-0.mol
• Article Data: 21

Chemical Properties

• CAS DataBase Reference: Benzene, 4-azido-1,2-dimethoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 4-azido-1,2-dimethoxy-(87587-62-0)
• EPA Substance Registry System: Benzene, 4-azido-1,2-dimethoxy-(87587-62-0)

Safety Data

• Hazardous Substances Data: 87587-62-0(Hazardous Substances Data)

Upstream product

• 51186-35-7 3,4-dimethoxy-benzenediazonium; chloride 
• 122775-35-3 3,4-Dimethoxyphenylboronic acid 
• 6315-89-5 3,4-dimethoxyaniline 
• 85656-27-5 (3,4-Dimethoxyphenyl)lead triacetate 

Downstream Products

• 960306-80-3 1-(3,4-dimethoxyphenyl)-1H-benzo[d][1,2,3]triazole 
• 1268445-36-8 C₂₀H₂₁N₃O₆ 
• 1313994-66-9 1-(3,4-dimethoxyphenyl)-4-phenyl-1H-1,2,3-triazole 
• 1600529-60-9 1-(3,4-dimethoxyphenyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione 

Relevant articles and documents

3, 4-dihydroxy methyl benzoate derivative, preparation method and application thereof

The invention relates to the technical field of medicines, in particular to a 3, 4-dihydroxy methyl benzoate derivative, a preparation method and application thereof, and discloses a 3, 4-dihydroxy methyl benzoate derivative with a structure as shown in a

Synthesis, and evaluation of in vitro and in vivo anticancer activity of 14-substituted oridonin analogs: A novel and potent cell cycle arrest and apoptosis inducer through the p53-MDM2 pathway

A series of novel oridonin derivatives bearing various substituents on the 14-OH position were designed and synthesised. Their antitumour activity was evaluated in vitro against three human cancer cell lines (HCT116, BEL7402, and MCF7). Most tested derivatives showed improved anti-proliferative activity compared to the lead compound oridonin and the positive control drug 5-fluorouracil (5-Fu). Among them, compound C7 (IC50 = 0.16 μM) exhibited the most potent anti-proliferative activity against HCT116 cells; it was about 43- and 155-fold more efficacious than that of oridonin (IC50 = 6.84 μM) and 5-Fu (IC50 = 24.80 μM) in HCT116 cancer cells. Interestingly, the IC50 value of compound C7 in L02 normal cells was 23.6-fold higher than that in HCT116 cells; it exhibited better selective anti-proliferative activity and specificity than oridonin and 5-Fu. Furthermore, compound C7 possibly induced cell cycle arrest and apoptosis by regulating the p53-MDM2 signalling pathway. Notably, C7 displayed more significant suppression of tumour growth than oridonin in colon tumour xenograft models where the tumour growth inhibition rate was 85.82%. Therefore, compound C7 could be a potential lead compound for the development of a novel antitumour agent.

Aryl Azides as Forgotten Electrophiles in the Van Leusen Reaction: A Multicomponent Transformation Affording 4-Tosyl-1-arylimidazoles

Considering aryl azides as electrophilic partners for the TosMIC mediated Van Leusen reaction, a novel multicomponent synthesis of 4-tosyl-1-arylimidazoles is reported. In this transformation, two molecules of TosMIC participate in the reaction mechanism